齐拉西酮对30例精神分裂症患者生活质量的影响

Effect of Ziprasidone on Quality of Life in 30 Cases of Schizophrenia

目的观察齐拉西酮对精神分裂症患者生活质量的影响。方法选取符合CCMD-3诊断标准的精神分裂症患者62例,随机分为两组,治疗组30例给予齐拉西酮80～160mg/d,对照组32例给予氯氮平300～500mg/d,均口服。治疗6个月后观察两组患者精神症状及生活质量的改变。结果两组患者的精神分裂症阳性、阴性症状及PANSS总分的改善情况相似,差异无显著性(P>0.05);治疗6个月后,治疗组患者生活质量的改变除精神支柱外,其他均非常明显地提高;对照组患者生活质量部分提高,但在生理领域、心理领域、独立性领域方面没有明显改善。结论齐拉西酮比氯氮平更能改善精神分裂症患者的生活质量。

Objective To survey the quality of life in the patients with schizophrenia treated with ziprasidone. Methods 62 patients meeting the CCMD-3 diagnostic criteria for schizophrenia were assigned to 2 groups, the treatment group （n--30） and the control group （n=32）. The patient of the treatment group was given oral ziprasidone 80- 160 mg/d, twice daily; the patient of the control group was orally given clozapine 300-500 mg/d, twice daily. The course of treatment in both groups lasted 6 months. The Positive and Negative Symptom Scale （PANSS） was used to assess the therapeutic effectiveness, and changes in the quality of life in all of the patients. Results The differences were not significant between the 2 groups with respect to the changes in the positive and negative symptoms of schizophrenia as well as the total scores of PANSS（P〉 0.05）. After 6-month treatment, the striking improvement was demonstrated almost in every aspect of the quality of life in the patients treated with ziprasidone except for the spiritual pillar. In contrast, only partial improvement in the quality of life was shown in the patients treated with clozapine, which had no help to the schizophrenics in the domains of physiology, psychology and independent character. Conclusion Ziprasidone is superior to clozapine in improving the schizoprenics quality of life.